Sutro Biopharma, INC 8-K filings

Sutro Biopharma announced second quarter 2026 financial results, highlighting encouraging early clinical data for its STRO-004 ADC candidate and progress across its pipeline, while cash reserves remain strong.

Sutro Biopharma, Inc. announced the results of its 2026 Annual Meeting of Stockholders, including the election of directors and ratification of its independent auditor.

Sutro Biopharma announced improved full year 2025 financial results, significant pipeline advancements, and an extended cash runway into Q2 2028 following a recent capital raise.

Sutro Biopharma announced a public offering of 7.87 million common shares at $13.98 each, raising approximately $110 million to extend its cash runway into Q2 2028.

Sutro Biopharma, Inc. announced it has regained compliance with Nasdaq's minimum bid price requirement, closing a previously disclosed listing matter.

Sutro Biopharma, Inc. will implement a 1-for-10 reverse stock split effective December 3, 2025, to regain Nasdaq compliance.

Sutro Biopharma announced its third quarter 2025 financial results, highlighted by FDA IND clearance for STRO-004 and an extended cash runway into mid-2027.

Sutro Biopharma announced an organizational restructuring, including a workforce reduction, to prioritize ADC programs and extend its cash runway into at least mid-2027.

Sutro Biopharma announced improved second-quarter 2025 financial results, driven by increased revenue and reduced expenses, while advancing its oncology pipeline.

Sutro Biopharma, Inc. has received a notice from NASDAQ indicating non-compliance with the $1.00 minimum bid price requirement, initiating a 180-day period to regain compliance.

Sutro Biopharma, Inc. announced that its stockholders approved a reverse stock split, the election of three Class I directors, and other key proposals at its 2025 Annual Meeting.

Sutro Biopharma, Inc. announced the appointment of Gregory K. Chow as its new Chief Financial Officer, principal financial officer, and principal accounting officer, effective June 2, 2025.

Sutro Biopharma shifts focus to next-generation antibody drug conjugates (ADCs) and reports first quarter 2025 financial results, highlighting promising preclinical data and a strategic pipeline reprioritization.

John Freund, M.D., a member of Sutro Biopharma's Board of Directors since 2014, will not stand for re-election, with his term expiring after the Annual Meeting of Shareholders on June 6, 2025.

Sutro Biopharma is prioritizing its next-generation ADC pipeline, undergoing management changes, and reporting its full year 2024 financial results, including a strategic portfolio review.

Sutro Biopharma reports a 32% objective response rate and 96% disease control rate in the dose-optimization phase of its luveltamab tazevibulin trial for platinum-resistant ovarian cancer.

Sutro Biopharma reported its Q3 2024 financial results, highlighted by a 56% response rate for luvelta in combination with bevacizumab and progress in multiple clinical trials.

Sutro Biopharma reported its second quarter 2024 financial results, highlighting progress in clinical trials and collaborations, and provided an update on anticipated milestones.

Sutro Biopharma has appointed Sukhi Jagpal as a Class III director and member of the Audit Committee, effective August 8, 2024 and August 15, 2024 respectively.

Sutro Biopharma's 2024 Annual Meeting saw the election of two Class III directors, ratification of Ernst & Young as auditor, and approval of executive compensation and an ESPP amendment.

Sutro Biopharma reported its first quarter 2024 financial results, highlighted by clinical advancements and a strengthened cash position through strategic licensing and financing activities.

Sutro Biopharma has entered into an underwriting agreement to sell 14,478,764 shares of its common stock at $5.18 per share, aiming to raise approximately $75 million before expenses.

Sutro Biopharma has granted Ipsen exclusive global rights to develop and commercialize STRO-003, an antibody-drug conjugate, in a deal that includes upfront payments, equity investments, and potential milestone payments.

Sutro Biopharma announced its full year 2023 financial results, highlighting progress in clinical trials, pipeline development, and a strong cash position.

Sutro Biopharma has filed a prospectus supplement to increase the amount of common stock it can sell through its existing sales agreement by $100 million.